View More Recent Stories
-
Tonix Pharma (TNXP) Presented Data on the Potential Mpox Vaccine TNX-801 in “Using Synthetic Biology to Battle Mpox” Talk at Immunology Symposium at the University of Alberta
-
As Research Into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront – Tonix Targets It With FDA-Fast Track-Designated TNX-102 SL
-
Tonix Pharma (TNXP) Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing
-
Tonix Pharma (TNXP) Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium
-
Tonix Pharma (TNXP) and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix’s Mpox Vaccine, TNX-801
-
Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency
-
Tonix Pharma (TNXP) Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication
-
Mpox-linked stocks extend rally into second week
-
Tonix Pharma (TNXP) Misses Q2 EPS by 1405c
-
Tonix Pharma (TNXP) Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801
-
Tonix Pharma (TNXP) Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia
-
FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug Candidate
-
Tonix Pharma (TNXP) Granted Fast Track Designation by FDA for Tonmya for Fibromyalgia
-
Tonix Pharma (TNXP) Secures Up To $34 Million In Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum Antiviral
-
Beyond "One Bug, One Drug" - Tonix Pharmaceuticals Secures Up To $34 Million In Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum Antiviral
-
Tonix Pharma (TNXP) to File an NDA for Tonmya for the Management of Fibromyalgia
-
Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025
-
Tonix Pharma (TNXP) Prices 7.1M Share Offering at $0.57/sh
-
Tonix Pharma (TNXP) Announces Proposed Public Offering of Common Stock, Warrants
-
Tonix Pharma (TNXP) Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program
-
Tonix Pharma (TNXP) Prices 7.06M Share Offering at $0.57/sh
-
Tonix Pharma (TNXP) Announces Proposed Share and Warrant Offering
-
Tonix Pharma (TNXP) Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
Tonix Pharma (TNXP) Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya
-
Tonix Pharma (TNXP) Prices $4M Share and Warrant Offering at $1.065/sh
-
Tonix Pharma (TNXP) Announces Proposed Share Offering
